Melatonina
Anno: 1993
-
Titolo: Vitiligo: where do we stand?Riferimento:Pigment Cell Res. 1993 Mar;6(2):61-72.Azione della melatonina:Abnormalities in a putative melatonin receptor on melanocytes.Target:Several different pathogenetic mechanisms.
-
Riferimento:Eur J Cancer. 1993;29A(2):185-9.Azione della melatonina:Neuroimmunotherapy with low-dose IL-2 and MLT (50mg/day orally) is a biologically active and well tolerated strategy, capable of determining an apparent control of tumour growth in patients with advanced solid neoplasms.Target:Interleukin 2 (IL-2) plus .MLT
Anno: 1994
-
Riferimento:Ann N Y Acad Sci. 1994 May 31;719:502-25. Review.Azione della melatonina:No abstract available.Target:No abstract available.
-
Riferimento:Cancer Lett. 1994 Jun 15;81(1):95-8.Azione della melatonina:Melatonin(0,3nM)inhibited MCF7 cell growth, effect of melatonin was reduced by the co-administration of 5-FU.Target:5-fluorouracil (5-FU)
-
Riferimento:Oncology. 1994 May-Jun;51(3):288-95.Azione della melatonina:Nocturnal melatonin levels were significantly reduced by exposure to this weak alternating MF.Target:Magnetic fields (MFs)
-
Riferimento:J Pineal Res. 1994 May;16(4):215-22.Azione della melatonina:Antitumor effect through a cell-cycle-specific mechanism by delaying the entry of cells into mitosis.Target:Smaller cell and nuclear sizes
-
Titolo: Melatonin concentrations in pineal organ culture are suppressed by sera from tumor-bearing miceRiferimento:J Pineal Res. 1994 Aug;17(1):17-9.Azione della melatonina:Melatonin rhythmicity is suppressed in cancer patients.Target:Plasma borne tumor-associated factor (TAMF).
-
Riferimento:Life Sci. 1994;54(21):1531-43. Review.Azione della melatonina:Reduction of circulating levels of melatonin.Target:50/60-Hz MF
-
Riferimento:J Natl Cancer Inst. 1994 Jun 15;86(12):921-5.Azione della melatonina:Exposure to extremely low-frequency electromagnetic fields reduces the pineal gland's nocturnal production of the hormone melatonin.Target:Electric or magnetic fields.
-
Riferimento:Br J Cancer. 1994 Jan;69(1):196-9.Azione della melatonina:The concomitant administration of MLT (40 mg day orally) may increase the efficacy of low-dose IL-2 subcutaneous therapy.Tumour objective regression rate was 11/41 vs 1/39, P < 0.001.Target:Interleukin 2 (IL-2) plus MLT.